CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Zepbound, Lilly’s obesity drug, has overtaken Novo’s equivalent, Wegovy, in the US and now commands over 50 per cent of the ...

CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its ...

Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...

Eli Lilly shares dropped Thursday as Novo Nordisk notched a coverage win for its obesity drug, a sign of the competition in ...

With Wegovy in its portfolio, Novo Nordisk is a very good bet to continue being a winner. As it's currently considered something of an underdog, with its stock priced accordingly, it's also trading at ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...